TOKYO/BALTIMORE, Aug. 28, 2020 – Elixirgen Scientific announced today that it has entered into a master service agreement (MSA) with Otsuka Pharmaceuticals. Elixirgen Scientific provides Otsuka Pharmaceuticals with its proprietary Quick-Tissue™ differentiation technology that enables rapid and highly efficient differentiation of human induced pluripotent stem cells (hiPSCs) for deeper understanding on human disease biology in vitro.
“Otsuka Pharmaceutical is one of the most important clients for us to serve to advance drug discovery for better cure and therapy. This service agreement resonates with our mission to deliver better cure, faster and more efficiently with our stem cell differentiation technology. We also look forward to advancing Otsuka Pharmaceutical’s drug discovery effort with Elixirgen Scientific technology and services.” according to Kazuhiro Aiba, Ph.D., Vice President, General Manager of Japan Branch, Elixirgen Scientific
About Otsuka Pharmaceutical
Otsuka Pharmaceutical is a total health care company that is committed to a holistic approach to health and well-being of people based on the corporate philosophy of "Otsuka-people creating new products for better health worldwide" to create innovative products that contribute to the health of people around the world. In the medical-related business, Otsuka Pharmaceutical is engaged in research and development with the central nervous system area, cardiovascular/renal area, and oncology area as the most important areas.
About Elixirgen Scientific
Elixirgen Scientific, launched in 2016, is a Baltimore-based biotechnology company focused on stem cell-related technology. The company’s mission is to make stem cell innovation available to everyone. Elixirgen Scientific is now providing reagents and cells at an affordable price to help make research and other laboratory work more efficient.
Contact: +1-443-869-5420, [email protected]